URUP, Thomas et al. Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan. Acta Oncologica, [S. l.], v. 55, n. 4, p. 418–422, 2016. DOI: 10.3109/0284186X.2015.1114679. Disponível em: https://medicaljournalssweden.se/actaoncologica/article/view/25239. Acesso em: 7 oct. 2024.